How to buy Corcept Therapeutics Incorporated stock (CORT)

Corcept Therapeutics Incorporated is a biotechnology business based in the US. Corcept Therapeutics Incorporated shares (CORT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $51.15 – a decrease of 7.67% over the previous week. Corcept Therapeutics Incorporated employs 352 staff and has a trailing 12-month revenue of around $628.6 million.

Our top picks for where to buy Corcept Therapeutics Incorporated stock

Buy Corcept Therapeutics Incorporated stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Corcept Therapeutics Incorporated stock price (NASDAQ: CORT)

Use our graph to track the performance of CORT stocks over time.

Corcept Therapeutics Incorporated shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$51.15
52-week range	$20.84 - $62.22
50-day moving average more info button	$53.21
200-day moving average more info button	$36.61
Wall St. target price	$74.90
PE ratio more info button	41.6032
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$1.26

Is it a good time to buy Corcept Therapeutics Incorporated stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Corcept Therapeutics Incorporated price performance over time

Historical closes compared with the close of $52.42 from 2024-12-18

1 week (2024-12-13)	-5.38%
1 month (2024-11-20)	-6.54%
3 months (2024-09-20)	24.07%
6 months (2024-06-20)	78.30%

1 year (2023-12-20)	69.75%
2 years (2022-12-20)	155.46%
3 years (2021-12-20)	152.02%
5 years (2019-12-20)	316.03%

Is Corcept Therapeutics Incorporated stock undervalued or overvalued?

Valuing Corcept Therapeutics Incorporated stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Corcept Therapeutics Incorporated's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Corcept Therapeutics Incorporated's P/E ratio

Corcept Therapeutics Incorporated's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 42x. In other words, Corcept Therapeutics Incorporated shares trade at around 42x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Corcept Therapeutics Incorporated's PEG ratio

Corcept Therapeutics Incorporated's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.61. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Corcept Therapeutics Incorporated's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Corcept Therapeutics Incorporated's EBITDA

Corcept Therapeutics Incorporated's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $144.1 million.

The EBITDA is a measure of a Corcept Therapeutics Incorporated's overall financial performance and is widely used to measure a its profitability.

Corcept Therapeutics Incorporated financials

Revenue TTM	$628.6 million
Operating margin TTM	25.53%
Gross profit TTM	$396.5 million
Return on assets TTM	13%
Return on equity TTM	25.77%
Profit margin	22.56%
Book value	$6.10
Market Capitalization more info button	$5.5 billion

TTM: trailing 12 months

Corcept Therapeutics Incorporated share dividends

We're not expecting Corcept Therapeutics Incorporated to pay a dividend over the next 12 months.

Corcept Therapeutics Incorporated share price volatility

Over the last 12 months, Corcept Therapeutics Incorporated's shares have ranged in value from as little as $20.84 up to $62.22. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Corcept Therapeutics Incorporated's is 0.455. This would suggest that Corcept Therapeutics Incorporated's shares are less volatile than average (for this exchange).

Corcept Therapeutics Incorporated overview

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California. .

Frequently asked questions

null
What percentage of Corcept Therapeutics Incorporated is owned by insiders or institutions?
Currently 11.518% of Corcept Therapeutics Incorporated shares are held by insiders and 85.49% by institutions. How many people work for Corcept Therapeutics Incorporated?
Latest data suggests 352 work at Corcept Therapeutics Incorporated. When does the fiscal year end for Corcept Therapeutics Incorporated?
Corcept Therapeutics Incorporated's fiscal year ends in December. Where is Corcept Therapeutics Incorporated based?
Corcept Therapeutics Incorporated's address is: 149 Commonwealth Drive, Menlo Park, CA, United States, 94025 What is Corcept Therapeutics Incorporated's ISIN number?
Corcept Therapeutics Incorporated's international securities identification number is: US2183521028 What is Corcept Therapeutics Incorporated's CUSIP number?
Corcept Therapeutics Incorporated's Committee on Uniform Securities Identification Procedures number is: 218352102